RxDoctor Payments Data

Katherine Hemberg

Nurse Practitioner · Madison, NCNPI 1295001618

Payments from drug & device makers

$3,557in general payments, 2019–2025

Across 65 payments — averaging $54.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$824
  • AstraZeneca$809
  • AbbVie$495
  • Novo Nordisk$386
  • Exact Sciences$355
  • GSK$240
  • plus $447 from 9 others

What the payments were for

  • Food & beverage$3,557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,557 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,542
Medicare patients
43
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$37,232
OzempicSemaglutide24$36,141
EliquisApixaban53$34,725
JardianceEmpagliflozin45$32,249
JanuviaSitagliptin Phosphate20$26,280
TrulicityDulaglutide17$23,833
FarxigaDapagliflozin Propanediol35$19,595
XareltoRivaroxaban20$18,215
MyrbetriqMirabegron31$16,602
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,369
LinzessLinaclotide27$14,202
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,581
Breo ElliptaFluticasone/Vilanterol20$7,699
TrintellixVortioxetine Hydrobromide11$5,162
Varenicline Tartrate15$4,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$824$61,06552 claims
PfizerEliquis, Premarin$17$38,66467 claims
Novo NordiskOzempic$386$36,14124 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$809$32,61369 claims
GSKTrelegy Ellipta, Breo Ellipta$240$22,06842 claims
Johnson & JohnsonXarelto$123$18,21520 claims
AbbVieLinzess, Synthroid$495$17,00957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Madison

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →